Successful control of dasatinib-related chylothorax by the Japanese Herbal Medicine “Goreisan”

Hisashi Sasaki; Yoshifumi Kimizuka; Hiraku Ogata; Yosuke Okada; Shinichiro Ota; Tomoya Sano; Chie Watanabe; Yohei Maki; Takayuki Yamamoto; Yoichi Tagami; Jun Miyata; Nobuyoshi Hayashi; Yuji Fujikura; Akihiko Kawana

doi:10.2169/internalmedicine.3002-19

Successful control of dasatinib-related chylothorax by the Japanese Herbal Medicine “Goreisan”

Hisashi Sasaki, Yoshifumi Kimizuka, Hiraku Ogata, Yosuke Okada, Shinichiro Ota, Tomoya Sano, Chie Watanabe, Yohei Maki, Takayuki Yamamoto, Yoichi Tagami, Jun Miyata, Nobuyoshi Hayashi, Yuji Fujikura, Akihiko Kawana

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Dasatinib-related chylothorax is a rare adverse event, and the mechanism underlying its occurrence is still not fully understood. We herein report the case of a 73-year-old woman with chronic myeloid leukemia (CML) who developed dasatinib-related chylothorax refractory to conventional treatments, except for steroids. To the best of our knowledge, this is the first case of dasatinib-related chylothorax which was successfully controlled by combining diuretics with the Japanese herbal medicine “Goreisan.” “Goreisan” is known to inhibit aquaporin channels and regulate the water flow. Our findings showed that “Goreisan” is an effective treatment option for uncontrollable dasatinib-related chylothorax.

Original language	English
Pages (from-to)	3139-3141
Number of pages	3
Journal	Internal Medicine
Volume	58
Issue number	21
DOIs	https://doi.org/10.2169/internalmedicine.3002-19
Publication status	Published - 2019
Externally published	Yes

Keywords

Aquaporin
Chronic myeloid leukemia
Chylothorax
Dasatinib
Goreisan

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.2169/internalmedicine.3002-19

Cite this

@article{f8378ac33c884096828abaf417abceb5,

title = "Successful control of dasatinib-related chylothorax by the Japanese Herbal Medicine “Goreisan”",

abstract = "Dasatinib-related chylothorax is a rare adverse event, and the mechanism underlying its occurrence is still not fully understood. We herein report the case of a 73-year-old woman with chronic myeloid leukemia (CML) who developed dasatinib-related chylothorax refractory to conventional treatments, except for steroids. To the best of our knowledge, this is the first case of dasatinib-related chylothorax which was successfully controlled by combining diuretics with the Japanese herbal medicine “Goreisan.” “Goreisan” is known to inhibit aquaporin channels and regulate the water flow. Our findings showed that “Goreisan” is an effective treatment option for uncontrollable dasatinib-related chylothorax.",

keywords = "Aquaporin, Chronic myeloid leukemia, Chylothorax, Dasatinib, Goreisan",

author = "Hisashi Sasaki and Yoshifumi Kimizuka and Hiraku Ogata and Yosuke Okada and Shinichiro Ota and Tomoya Sano and Chie Watanabe and Yohei Maki and Takayuki Yamamoto and Yoichi Tagami and Jun Miyata and Nobuyoshi Hayashi and Yuji Fujikura and Akihiko Kawana",

note = "Publisher Copyright: {\textcopyright} 2019 The Japanese Society of Internal Medicine.",

year = "2019",

doi = "10.2169/internalmedicine.3002-19",

language = "English",

volume = "58",

pages = "3139--3141",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "21",

}

TY - JOUR

T1 - Successful control of dasatinib-related chylothorax by the Japanese Herbal Medicine “Goreisan”

AU - Sasaki, Hisashi

AU - Kimizuka, Yoshifumi

AU - Ogata, Hiraku

AU - Okada, Yosuke

AU - Ota, Shinichiro

AU - Sano, Tomoya

AU - Watanabe, Chie

AU - Maki, Yohei

AU - Yamamoto, Takayuki

AU - Tagami, Yoichi

AU - Miyata, Jun

AU - Hayashi, Nobuyoshi

AU - Fujikura, Yuji

AU - Kawana, Akihiko

PY - 2019

Y1 - 2019

N2 - Dasatinib-related chylothorax is a rare adverse event, and the mechanism underlying its occurrence is still not fully understood. We herein report the case of a 73-year-old woman with chronic myeloid leukemia (CML) who developed dasatinib-related chylothorax refractory to conventional treatments, except for steroids. To the best of our knowledge, this is the first case of dasatinib-related chylothorax which was successfully controlled by combining diuretics with the Japanese herbal medicine “Goreisan.” “Goreisan” is known to inhibit aquaporin channels and regulate the water flow. Our findings showed that “Goreisan” is an effective treatment option for uncontrollable dasatinib-related chylothorax.

AB - Dasatinib-related chylothorax is a rare adverse event, and the mechanism underlying its occurrence is still not fully understood. We herein report the case of a 73-year-old woman with chronic myeloid leukemia (CML) who developed dasatinib-related chylothorax refractory to conventional treatments, except for steroids. To the best of our knowledge, this is the first case of dasatinib-related chylothorax which was successfully controlled by combining diuretics with the Japanese herbal medicine “Goreisan.” “Goreisan” is known to inhibit aquaporin channels and regulate the water flow. Our findings showed that “Goreisan” is an effective treatment option for uncontrollable dasatinib-related chylothorax.

KW - Aquaporin

KW - Chronic myeloid leukemia

KW - Chylothorax

KW - Dasatinib

KW - Goreisan

UR - http://www.scopus.com/inward/record.url?scp=85074553104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074553104&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.3002-19

DO - 10.2169/internalmedicine.3002-19

M3 - Article

C2 - 31292394

AN - SCOPUS:85074553104

SN - 0918-2918

VL - 58

SP - 3139

EP - 3141

JO - Internal Medicine

JF - Internal Medicine

IS - 21

ER -

Successful control of dasatinib-related chylothorax by the Japanese Herbal Medicine “Goreisan”

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this